Regulatory bodies worldwide are increasingly tasked with evaluating the safety and effectiveness of psychedelic therapies.
The IPEA Working Group convenes a multidisciplinary team of experts to critically assess existing frameworks for evidence evaluation and to consider their suitability for psychedelic treatments.
Our goal is to provide sound expert recommendations based on multidisciplinary perspectives that are firmly anchored in the pluralistic advances of the philosophy of evidence and causality in medicine.
Members are selected renowned scientists, philosophers and health experts who are not involved in psychedelic research and have no conflicts of interest.
Speakers at meetings are selected leading psychedelic researchers from many fields, including pharmacology and cellular biology, neuroimaging, clinical trials, causal inference, psychotherapy, lived experience from patients from past studies, and an indigenous expert. All with as little conflicts of interest as possible, necessarily disclosed.
IPEA-WG Chairs
-
Eduardo Schenberg, MSc, PhD
Researcher, Faculdade de Medicina da Universidade de Lisboa
-
Franklin King, MD
Instructor, Mass General Hospital
-
Marion Haberkamp, MD
Head of unit, Bundesinstitut für Arzneimittel und Medizinprodukte
IPEA-WG Members
-
Serife Tekin, PhD
Associate Professor, SUNY Upstate Medical University
-
Rani Lill Anjum, PhD
Research Professor, Norwegian University of Life Sciences
-
Jon Williamson, BsC, MsC, PhD
Professor of Philosophy, University of Manchester
-
Mariusz Maziarz, PhD
Assistant Professor, Jagiellonian University
-
Sarah Wieten, MA, PhD
Assistant Professor, Philosophy, University of Durham
-
Mazviita Chirimuuta, BSc, PhD
Senior Lecturer, University of Edinburgh
-
Jonathan Fuller, MD, PhD
Associate Professor of History and Philosophy of Science, University of Pittsburgh
IPEA-WG Speakers
-
Max Wolff, Dr. rer. nat.
Associate Researcher, Central Institute of Mental Health, Mannheim, & Charité Berlin
-
Michiel van Elk, PhD
Associate Professor, Leiden University
-
Bryan Roth, MD, PhD
Professor, UNC - University of North Carolina at Chapel Hill
-
Charles Raison, MD
Professor, University of Wisconsin-Madison
-
Yuria Celidwen, PhD
Research Scientist, University of California Berkeley
-
Suresh Muthukumaraswamy, PhD
Professor, The University of Auckland
-
Gitte Moos Knudsen, MD, DMSc
Professor, Copenhagen University Hospital Rigshospitalet
IPEA-WG Other Participants
-
Dilkushi Poovendran, MSc, PhD
Expert Observer
Technical Officer, World Health Organization -
Sahanika Ratnayake, PhD
Observer
Research Associate, University of Manchester -
Kenneth Tupper, PhD
Observer
Adjunct Assistant Professor, University of Victoria -
Diogo Telles Correia, MD, PhD
Senior Advisor
Professor, Universidade de Lisboa -
Pedro Zuzarte, MD, PhD
Supervisor
Professor, Universidade de Lisboa
Featured publications
-
![Artificial intelligence, consciousness and psychiatry]()
Artificial intelligence, consciousness and psychiatry
Authors: Giulio Tononi, Charles Raison
World Psychiatry. 2024 Oct;23(3):309-310. doi: 10.1002/wps.21222. PMID: 39279409; PMCID: PMC11403160.
-
![Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experience]()
Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experience
Authors: Nicholas CR, Banks MI, Lennertz RC, Wenthur CJ, Krause BM, Riedner BA, Smith RF, Hutson PR, Sauder CJ, Dunne JD, Roseman L, Raison CL
Transl Psychiatry. 2024 Sep 12;14(1):372. doi: 10.1038/s41398-024-03059-8. PMID: 39266503; PMCID: PMC11393325.
-
![]()
Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial
Authors: Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, Kakar R, Hassman M, Trivedi RP, Robison R, Gukasyan N, Nayak SM, Hu X, O'Donnell KC, Kelmendi B, Sloshower J, Penn AD, Bradley E, Kelly DF, Mletzko T, Nicholas CR, Hutson PR, Tarpley G, Utzinger M, Lenoch K, Warchol K, Gapasin T, Davis MC, Nelson-Douthit C, Wilson S, Brown C, Linton W, Ross S, Griffiths RR.
JAMA, August 31, 2023 -
![Pharmacology Research & Perspectives: Volume 13, Issue 2 April 2025]()
From Efficacy to Effectiveness: Evaluating Psychedelic Randomized Controlled Trials for Trustworthy Evidence-Based Policy and Practice
Author: Eduardo Ekman Schenberg
Pharmacology Research & Perspectives, 15 April 2025
-
![Who is blind in psychedelic research? Letter to the editor regarding: blinding and expectancy confounds in psychedelic randomized controlled trials]()
Who is blind in psychedelic research? Letter to the editor regarding: blinding and expectancy confounds in psychedelic randomized controlled trials
Author: Eduardo Ekman Schenberg
Expert Review of Clinical Pharmacology, 14(10), 1317–1319.
-
![Psychedelic therapies: healing for the wrong reasons?]()
Psychedelic therapies: healing for the wrong reasons?
Authors: Eduardo Ekman Schenberg, Christine Hauskeller, Claudia Gertraud Schwarz & Franklin King IV
Nature Mental Health 2, 1265–1267 (2024).
-
![The Lancet Pyschiatry – Volume 11 - Number 3]()
Treatment with psychedelics is psychotherapy
Authors: Gerhard Gründer, Manuela Brand, Lea J Mertens, Henrik Jungaberle, Laura Kärtner, Dennis J Scharf, Moritz Spangemacher, Max Wolff
The Lancet Psychiatry, Volume 11, Issue 3, March 2024
-
![Reframing psychedelic regulation: Tools, not treatments]()
Reframing psychedelic regulation: Tools, not treatments
Authors: Max Wolff, Natalie Gukasyan, Leor Roseman, Paul Liknaitzky
Drug Science, Policy and Law, Volume 11, First published online June 16, 2025
-
![Measuring psychotherapeutic processes in the context of psychedelic experiences: Validation of the General Change Mechanisms Questionnaire (GCMQ)]()
Measuring psychotherapeutic processes in the context of psychedelic experiences: Validation of the General Change Mechanisms Questionnaire (GCMQ)
Authors: Max Wolff, Ricarda Evens, Lea J Mertens, Christopher Schmidt Jessica Beck, Hans Rutrecht, Aaron D Cherniak, Gerhard Gründer, Henrik Jungaberle
Journal of Psychopharmacology, Volume 38, Issue 5, Pages: 432 - 457
-
![The polypharmacology of psychedelics reveals multiple targets for potential therapeutics]()
The polypharmacology of psychedelics reveals multiple targets for potential therapeutics
Authors: JF, Keiser M, Hauser AS, Dror RO, Shoichet B, Gloriam DE, Nichols DE, Roth BL
Neuron • Neuroresource, July 18, 2025
-
![The structural diversity of psychedelic drug actions revealed]()
The structural diversity of psychedelic drug actions revealed
Authors: Gumpper RH, Jain MK, Kim K, Sun R, Sun N, Xu Z, DiBerto JF, Krumm BE, Kapolka NJ, Kaniskan HÜ, Nichols DE, Jin J, Fay JF, Roth BL
Nature Communications. 2025 Mar 19;16(1):2734.
-
![]()
Rethinking Causality, Complexity and Evidence for the Unique Patient
Editors: Rani Lill Anjum, Samantha Copeland, Elena Rocca
Book • Open Access © 2020
-
![Causation in Science and the Methods of Scientific Discovery]()
Causation in Science and the Methods of Scientific Discovery
Authors: Rani Lill Anjum, Stephen Mumford
Book, Oxford University Press, 2018
-
![Philosophy of Science]()
Philosophy of Science
Authors: Rani Lill Anjum, Elena Rocca
Textbook, 2024. Part of the book series: Palgrave Philosophy Today.
-
![CLEVELAND CLINIC JOURNAL OF MEDICINE]()
Psychedelic-assisted therapy: An overview for the internist
Authors: Brian S Barnett, Erin E Mauney, Franklin King
Cleveland Clinic Journal of Medicine, Vol. 92, Issue 3, 1 Mar 2025
-
![Psychedelic-assisted Therapy as a Promising Treatment for Irritable Bowel Syndrome]()
Psychedelic-assisted Therapy as a Promising Treatment for Irritable Bowel Syndrome
Authors: Erin Mauney, Franklin King 4th, Helen Burton-Murray, Braden Kuo
J Clin Gastroenterol. 2025 May-Jun;59(5):385-392.
-
![Evaluating Evidence of Mechanisms in Medicine]()
Evaluating Evidence of Mechanisms in Medicine
Authors: Veli-Pekka Parkkinen, Christian Wallmann, Michael Wilde, Brendan Clarke, Phyllis Illari, Michael P Kelly, Charles Norell, Federica Russo, Beth Shaw, Jon Williamson
Book • Open Access © 2018 -
![The use of mechanistic evidence in drug approval]()
The use of mechanistic evidence in drug approval
Authors: Jeffrey K. Aronson MA, DPhil, FRCP, HonFBPhS, HonFFPM, Adam La Caze BPharm, PGDipClinPharm, BA(Hons), PhD, Michael P. Kelly PhD, FRCP (Hon), FRCPE, FFPH, Veli-Pekka Parkkinen PhD, Jon Williamson PhD
Journal of Evaluation in Clinical Practice (JECP), Volume24, Issue5, October 2018, Pages 1166-1176
-
![Establishing Causal Claims in Medicine]()
Establishing Causal Claims in Medicine
Author: Jon Williamson
International Studies in the Philosophy of Science Volume 32, 2019 - Issue 1
-
![ACS Pharmacology & Translational Science]()
Applying the EU Regulatory Framework to Determine the Benefit–Risk Profile of Psychedelics
Authors: Kate Browne, Ewa Bałkowiec-Iskra, Andre Elferink, Marion Haberkamp, Sabine Straus, Bruno Sepodes, Francisca Silva, Florence Butlen-Ducuing, Jarno Jansen, Ivana Silva, Pavel Balabanov, Juan Garcia Burgos, Steffen Thirstrup
ACS Pharmacology & Translational Science, Published July 18, 2025
-
![Tofersen for SOD-1-associated amyotrophic lateral sclerosis]()
Tofersen for SOD-1-associated amyotrophic lateral sclerosis
Authors: Marion Haberkamp, Georgios Aislaitner, Elena H Martínez-Lapiscina, Martina Weise
In Context / In the clinic, The Lancet Neurology, Volume 23, Issue 8, August 2024
-
![EU regulatory horizons for Alzheimer's disease]()
EU regulatory horizons for Alzheimer's disease
Authors: Oriane Blanquie, Lorenzo Guizzaro, Ralf Herold, Marion Haberkamp, André Elferink, Pavel Balabanov, Falk Ehman
The Lancet Neurology, Volume 24, Issue 2, p96-97, February 2025
-
![Flourishing Kin: Indigenous Wisdom for Collective Well-Being]()
Flourishing Kin: Indigenous Wisdom for Collective Well-Being
Author: Yuria Celidwen PhD
Book published by Sounds True, 2024, ISBN: 1649632045, 9781649632043, 256 pages
-
![]()
Ethical principles of traditional Indigenous medicine to guide western psychedelic research and practice
Author: Yuria Celidwen
The Lancet Americas, Feb 2023, Volume 18
-
![Kin relationality and ecological belonging: a cultural psychology of Indigenous transcendence]()
Kin relationality and ecological belonging: a cultural psychology of Indigenous transcendence
Authors: Yuria Celidwen, Dacher Keltner
Frontiers Psychology, 19 October 2023
Sec. Cultural Psychology
Volume 14 - 2023 -
![Mictlán: Our Shared Home – Indigenous Contemplative Sciences through Transcendence and Remembrance]()
Mictlán: Our Shared Home – Indigenous Contemplative Sciences through Transcendence and Remembrance
Chapter:
Mictlán: Our Shared Home – Indigenous Contemplative Sciences through Transcendence and RemembranceAuthor: Yuria Celidwen
Book: The Routledge Handbook of Research Methods in Spirituality and Contemplative Studies, 1st Edition, Published 2024, by Routledge
-
![NT-proBNP is a potential mediator between reduced ejection fraction and depression in patients with heart failure]()
NT-proBNP is a potential mediator between reduced ejection fraction and depression in patients with heart failure
Authors: Pedro Zuzarte, Gustavo Scola, Angela Duong, Kari Kostiw, Maria L. Figueira, Atilio Costa-Vitali
Journal of Psychiatric Research, Volume 104, 2018
-
![Therapeutic Opportunities for Food Supplements in Neurodegenerative Disease and Depression]()
Therapeutic Opportunities for Food Supplements in Neurodegenerative Disease and Depression
Authors: Rita Businaro, David Vauzour, Jerome Sarris, Gerald Münch, Erika Gyengesi, Laura Brogelli, Zuzarte Pedro
REVIEW article / Frontiers in Nutrition, 13 May 2021, Sec. Nutrition, Psychology and Brain Health, Volume 8 - 2021
-
![]()
Current Therapeutic Approaches for Targeting Inflammation in Depression and Cardiovascular Disease
Authors: Pedro Zuzarte, Angela Duong, Maria L. Figueira, Atilio Costa-Vitali and Gustavo Scola
Current Drug Metabolism, Volume 26, Issues 10, 2025
-
![Dark Loops: Contagion effects, consistency and chemosocial matrices in psychedelic-assisted therapy trials]()
Dark Loops: Contagion effects, consistency and chemosocial matrices in psychedelic-assisted therapy trials
Authors: Tehseen Noorani, Gillinder Bedi, and Suresh Muthukumaraswamy
PsyArXiv, 2023, February 6
-
![]()
Overcoming blinding confounds in psychedelic randomized controlled trials using biomarker driven causal mediation analysis
Author: Suresh Muthukumaraswamy
Expert Review of Clinical Pharmacology, 16(12), 1163–1173. Published online: 26 Aug 2021
-
![Psychedelic-assisted therapy as a complex intervention: implications for clinical trial design]()
Psychedelic-assisted therapy as a complex intervention: implications for clinical trial design
Authors: Muthumaraswamy SD, Baggott MJ, Schenberg EE, Wolff M, et al.
Therapeutic Advances in Psychopharmacology. 2025;15.
-
![Acute psilocybin and ketanserin effects on cerebral blood flow: 5-HT2AR neuromodulation in healthy humans]()
Acute psilocybin and ketanserin effects on cerebral blood flow: 5-HT2AR neuromodulation in healthy humans
Authors: Kristian Larsen, Ulrich Lindberg, Brice Ozenne, Drummond E McCulloch, Sophia Armand, Martin K Madsen, Annette Johansen, Dea S Stenbaek, Gitte M Knudsen, Patrick M Fisher
Published in Journal of Cerebral Blood Flow & Metabolism, Volume 45, Issue 7, Pages: 1385 - 1401, July 2025
-
![CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity]()
CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity
Authors: Martin K Madsen, Anja Sofie Petersen, Dea S Stenbaek, Inger Marie Sørensen, Harald Schiønning, Tobias Fjeld, Charlotte H Nykjaer, Sara Marie Ulv Larsen, Maria Grzywacz, Tobias Mathiesen, Ida L Klausen, Oliver Overgaard-Hansen, Kristoffer Brendstrup-Brix, Kristian Linnet, Sys S Johansen, Patrick M Fisher, Rigmor H Jensen, Gitte M Knudsen
Headache: The Journal of Head and Face Pain: Volume 64, Issue 4
-
![Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels]()
Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels
Authors: Martin K Madsen, Patrick M Fisher, Daniel Burmester, Agnete Dyssegaard, Dea S Stenbæk, Sara Kristiansen, Sys S Johansen, Sczabolz Lehel, Kristian Linnet, Claus Svarer, David Erritzoe, Brice Ozenne, Gitte M Knudsen
Neuropsychopharmacology. 2019 Jun; 44(7):1328-1334.
-
![WHO Expert Committee on Drug Dependence 44th report]()
WHO Expert Committee on Drug Dependence 44th report
Organized under the overall direction of Mariângela Simão (WHO Division of Access to Medicines and Health Products, Geneva, Switzerland) and Gilles Forte (Geneva, Switzerland). Dilkushi Poovendran (Geneva, Switzerland) coordinated the work of the meeting with the support of Suzanne Nielsen and Tina Lam (Monash University, Melbourne, Australia) and Judith Sprunken and Patricia Gevrey (WHO, Geneva, Switzerland).
World Health Organization, WHO technical report series;1038, 15 March 2022
-
![WHO Expert Committee on Drug Dependence 41st report]()
WHO Expert Committee on Drug Dependence 41st report
Expert Committee on Drug Dependence (ECDD) Secretariat (WHO Headquarters, Geneva, Switzerland): Alma Alic, Gilles Forte, Dilkushi Poovendran, Vladimir Poznyak, Jakob Quirin, Mariângela Simão, Wil de Zwart
World Health Organization, WHO Technical Report Series, No. 1018, November 2018
-
![The Brain Abstracted Simplification in the History and Philosophy of Neuroscience]()
The Brain Abstracted Simplification in the History and Philosophy of Neuroscience
Author: Mazviita Chirimuuta
Book published by The MIT Press, 376 pp., 6 x 9 in, 7 b&w illus., March 5, 2024, ISBN 9780262548045
-
![Artifacts and levels of abstraction]()
Artifacts and levels of abstraction
Author: Mazviita Chirimuuta
REVIEW article published in Front. Ecol. Evol., 08 August 2022, Sec. Models in Ecology and Evolution, Volume 10 - 2022
-
![Problems with evidence assessment in COVID-19 health policy impact evaluation: A systematic review of study design and evidence strength]()
Problems with evidence assessment in COVID-19 health policy impact evaluation: A systematic review of study design and evidence strength
Authors: Noah A. Haber, Emma Clarke-Deelder, Avi Feller, Emily R. Smith, Joshua A. Salomon, Benjamin MacCormack-Gelles, Elizabeth M. Stone, Clara Bolster-Foucault, Jamie R. Daw, Laura Anne Hatfield, Carrie E. Fry, Christopher B. Boyer, Eli BenMichael, Caroline M. Joyce, Beth S. Linas, lan Schmid, Eric H. Au, Sarah E. Wieten, Brooke Jarrett, Cathrine Axfors, Van Thu Nguyen, Beth Ann Griffin, Alyssa Bilinski, Elizabeth A. Stuart
BMJ open, Volume 12, Issue 1, Published - Jan 11 2022
-
![DAG With Omitted Objects Displayed (DAGWOOD): a framework for revealing causal assumptions in DAGs]()
DAG With Omitted Objects Displayed (DAGWOOD): a framework for revealing causal assumptions in DAGs
Authors: Noah A Haber ScD, Mollie E Wood PhD, Sarah Wieten PhD, Alexander Breskin PhD
Annals of Epidemiology, Volume 68, April 2022, Pages 64-71
-
![Much ado about something: a response to “COVID-19: underpowered randomised trials, or no randomised trials?”]()
Much ado about something: a response to “COVID-19: underpowered randomised trials, or no randomised trials?”
Authors: Noah A. Haber, Sarah E. Wieten, Emily R. Smith & David Nunan
Trials, 22, Article number: 780 (2021), 07 November 2021
-
![Averaged versus individualized: pragmatic N-of-1 design as a method to investigate individual treatment response]()
Averaged versus individualized: pragmatic N-of-1 design as a method to investigate individual treatment response
Authors: Davide Serpico, Mariusz Maziarz
Paper in the Philosophy of the Life Sciences, Open access, Published: 14 December 2023, Volume 13, article number 59, (2023)
-
![Is meta-analysis of RCTs assessing the efficacy of interventions a reliable source of evidence for therapeutic decisions?]()
Is meta-analysis of RCTs assessing the efficacy of interventions a reliable source of evidence for therapeutic decisions?
Author: Mariusz Maziarz
Studies in History and Philosophy of Science, Volume 91, February 2022, Pages 159-167
-
![The failure of drug repurposing for COVID-19 as an effect of excessive hypothesis testing and weak mechanistic evidence]()
The failure of drug repurposing for COVID-19 as an effect of excessive hypothesis testing and weak mechanistic evidence
Authors: Mariusz Maziarz, Adrian Stencel
Original Paper, Open access, Published: 18 October 2022, Volume 44, article number 47, (2022)
-
![Reclaiming the Self in Psychiatry]()
Reclaiming the Self in Psychiatry
Author: Serife Tekin
Book • Published April 29, 2025 by Routledge
-
![Beyond Doomsday Fears: Why We Need to Consider the Potential Harms of AI Psychotherapy]()
Beyond Doomsday Fears: Why We Need to Consider the Potential Harms of AI Psychotherapy
Authors: Serife Tekin, Megan Delehanty
The American Journal of Bioethics, 1-11, 2025
-
![Participatory Interactive Objectivity in Psychiatry]()
Participatory Interactive Objectivity in Psychiatry
Author: Serife Tekin
Book, Participatory Interactive Objectivity in Psychiatry, 2022
-
![Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review]()
Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review
Authors: Michiel van Elk, David Bryce Yaden
Neuroscience & Biobehavioral Reviews, Volume 140, September 2022, 104793
-
![History repeating: guidelines to address common problems in psychedelic science]()
History repeating: guidelines to address common problems in psychedelic science
Authors: Michiel van Elk, Eiko I. Fried
Therapeutic Advances in Psychopharmacology, 13, 20451253231198466
-
![Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression]()
Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression
Authors: Daniel Meling, Rebecca Ehrenkranz, Sandeep M. Nayak, Helena D. Aicher, Xaver Funk, Michiel van Elk, Marianna Graziosi, Prisca R. Bauer, Milan Scheidegger, and David B. Yaden
Psychoactives 2024, 3(2), 215-234, 16 April 2024
-
![]()
The Inescapable Specificities of Psychiatry Across Research, Clinical Practice, and Medical Education
Author: Diogo Telles Correia
Journal of Evaluation in Clinical Practice: Volume 31, Issue 4
-
![The new European Medicines Agency guideline on antidepressants: a guide for researchers and drug developers]()
The new European Medicines Agency guideline on antidepressants: a guide for researchers and drug developers
Authors: Butlen-Ducuing F, Haberkamp M, Aislaitner G, Bałkowiec-Iskra E, Mattila T, Doucet M, Kollb-Sielecka M, Balabanov P, Leuchs AK, Elferink A
European Psychiatry. 2023 Dec 15;67(1):e2
-
![Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects]()
Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects
Authors: Drummond E-Wen McCulloch, Matthias E. Liechti, Kim PC. Kuypers, David Nutt, Johan Lundberg, Dea Siggaard Stenbæk, Guy M. Goodwin, Gerhard Gründer, Florence Butlen-Ducuing, Marion Haberkamp, Steffen Thirstrup, Gitte M. Knudsen
Neuroscience Applied, Volume 3, 2024, 103938, ISSN 2772-4085
-
![The Decline of Psychoanalysis and the Rise of Cognitive-Behavioral Therapy: Part I: Dismantling the Legend of CBT]()
The Decline of Psychoanalysis and the Rise of Cognitive-Behavioral Therapy: Part I: Dismantling the Legend of CBT
Author: Sahanika Ratnayake
Philosophy, Psychiatry, & Psychology, vol. 32 no. 1, 2025, p. 81-92. Project MUSE
-
![The Decline of Psychoanalysis and the Rise of Cognitive-Behavioral Therapy: Part II: The Challenge of Psychopharmaceuticals]()
The Decline of Psychoanalysis and the Rise of Cognitive-Behavioral Therapy: Part II: The Challenge of Psychopharmaceuticals
Author: Sahanika Ratnayake
Philosophy, Psychiatry, & Psychology, vol. 32 no. 1, 2025, p. 93-104. Project MUSE
-
![The argument framework is a flexible approach to evidence in healthcare]()
The argument framework is a flexible approach to evidence in healthcare
Authors: Jonathan Fuller, Benjamin Chin-Yee & Ross E. G. Upshur
Nature Medicine 30, 2113–2116 (2024)
-
![Nourishing the Spirit: Exploratory Research on Ayahuasca Experiences along the Continuum of Recovery from Eating Disorders]()
Nourishing the Spirit: Exploratory Research on Ayahuasca Experiences along the Continuum of Recovery from Eating Disorders
Authors: Lafrance A, Loizaga-Velder A, Fletcher J, Renelli M, Files N, Tupper KW.
2017 Nov-Dec;49(5):427-435. Epub 2017 Sep 12. PMID: 28895501.
-
![A Public-Health-Based Vision for the Management and Regulation of Psychedelics]()
A Public-Health-Based Vision for the Management and Regulation of Psychedelics
Authors: Haden M, Emerson B, Tupper KW.
J Psychoactive Drugs. 2016 Sep-Oct;48(4):243-52. Epub 2016 Jul 18. PMID: 27430375.
-
![Psychedelic medicine: a re-emerging therapeutic paradigm]()
Psychedelic medicine: a re-emerging therapeutic paradigm
Authors: Tupper KW, Wood E, Yensen R, Johnson MW.
CMAJ. 2015 Oct 6;187(14):1054-1059. Epub 2015 Sep 8. PMID: 26350908; PMCID: PMC4592297.
Get in touch.
Want to learn more about the IPEA-WG (Independent Psychedelic Evidence Based Assessment Working Group) or contribute with fresh ideas and perspectives? Fill out the form on our website and join this collective dialogue and exploration.
Subscribe to our newsletter
Sign up for news and updates.